Strategies to improve tolerability of rivastigmine: A case series

Current Medical Research and Opinion

Volumn 23, Issue 1, 2007, Pages 93-95

  Venkatesh, K ^a   Bullock, R ^a   Akbas A ^b  

^a VICTORIA HOSPITAL   (United Kingdom)

^b Mehmet Aydin State Hospital   (Turkey)

Author keywords

Cholinesterase inhibitor; Dementia; Rivastigmine; Titration; Tolerability

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; PLACEBO; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG INHIBITION; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFORMATION PROCESSING; MALE; MEDICAL RECORD; NAUSEA AND VOMITING; PARKINSON DISEASE; RECOMMENDED DRUG DOSE; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; PHENYLCARBAMATES;

EID: 33846674989     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X162791     Document Type: Article

References (9)

1. Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 2003;11:131-45
2. Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract 2002;127(Suppl 1):45-63
3. Weinstock M. Selectivity of cholinesterase inhibition. CNS Drugs 1999;12:307-23
4. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:55-65
5. Rösler M, Anand R, Cicin-Sain A, Gauthier S, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. Br Med J 1999;318:633-40
6. Anand R, Messina J, Hartman R. Dose-response effect of rivastigmine in the treatment of Alzheimer's disease. Int J Geriatr Psychopharmacol 2000;2:68-72
7. Bullock R, Touchon J, Bergman H, Gambina G, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005;21:1317-27
8. Grossberg GT. Cholinesterase inhibitors for the treatment of Alzheimer's disease: getting on and staying on. Curr Ther Res 2003;64:216-35
9. Agid Y, Dubois B, Anand R, Gharabawi G. Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Curr Ther Res 1998;59:837-45